secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akari Therapeutics Plc (AKTX)
CIK:        0001541157
Form:       8-K
Filed at:   2026-10-01T20:45:31+00:00
Accession:  0001493152-26-045364
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Akari Therapeutics raises CEO Gaslightwala's base salary to $625,000 from $475,000 and bonus target to 55%
--------------------------------------------------------------------------------

- Base salary raised from $475,000 to $625,000 effective Aug 18, 2026; $562,500 paid in cash and $62,500 delivered as RSUs over the 12 months beginning Aug 18, 2026.
- Target annual bonus lifted to 55% of base salary from 50%, for total target salary-plus-bonus of about $970,000, calculated on the full $625,000 base.
- 174,000 ADS options granted under the 2023 Equity Incentive Plan effective Aug 18, 2026, vesting monthly over four years with vesting deemed to begin March 18, 2026.
- RSUs vest in four quarterly installments from Nov 18, 2026 to Aug 18, 2027; RSUs and the 174,000 options are forfeited if shareholders do not approve a 2023 Plan ADS reserve increase.
- Amendment also restates the CEO agreement's existing equity: 1,100,000 ADS time-based option and 600,000 ADS performance option tied to Dec 31, 2025 financing or licensing milestones.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1541157/000149315226045364/0001493152-26-045364-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1541157/000149315226045364/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-045364

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer